Sofia Lindahl
Papers
1
Total Citations
50
H-Index
1
About
Sofia Lindahl is a leading researcher in clinical pharmacology and bioanalytical chemistry, with a primary focus on the therapeutic monitoring of direct oral anticoagulants (DOACs). Her major contribution lies in developing and validating a robust UHPLC-MS/MS method for the simultaneous quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in human serum. This work, published in 2018 and cited over 50 times, addresses a critical clinical need: while fixed-dose DOAC regimens are standard, measuring drug concentrations can be vital for managing patients with renal impairment, extreme body weight, or those requiring urgent surgery. By providing a reliable, validated analytical tool, Lindahl’s research enables personalized dosing strategies that could reduce the risk of bleeding or thrombosis. Her method’s application in clinical settings underscores its practical impact, bridging the gap between routine pharmacology and precision medicine. Lindahl’s work is foundational for researchers and clinicians seeking to optimize anticoagulation therapy, demonstrating her role as a key figure in advancing safe, evidence-based use of these life-saving drugs.
Research Focus
Key Achievements
Top Papers
- 1